- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04271995
Gastric Lipase Enhanced Nasogastric Tube Study in Neonates
A Diagnostic Accuracy Study Evaluating Point of Care Gastric Lipase Enhanced pH Test Strip to Confirm Correct Nasogastric Tube Position in Newborn Infant
Study Overview
Status
Conditions
Detailed Description
STUDY OBJECTIVES
Primary Objective:
• To determine the sensitivity of the chemical (tributyrin) impregnated pH test strip in comparison to the routine pH test strip to increase the sensitivity of detection of correct positioning of the nasogastric tube
Secondary objectives:
- To measure the number of nasogastric tube re-insertion attempts that could be avoided if the tributyrin impregnated pH test strip was used instead of the standard pH test strip
- To determine the number of chest radiographs which could be avoided if the tributyrin impregnated pH test strip was used instead of the standard pH test strip
- To carry out human factors assessment of perceived usability, trust and acceptance of the lipase-based pH test strip
STUDY DESIGN Prospective point of care diagnostic accuracy study
Primary outcome
• Sensitivity of proposed test in determining correct nasogastric (NG) tube position
Secondary outcomes
- Number of chest x rays performed
- Time to confirm tube placement
- Number of nasogastric tube attempts to get the correct pH
- Assessment of human factors - Perceived usability, trust and acceptance from professionals' perspective
Subject selection and setting
Participants will be recruited from Imperial College Healthcare NHS Trust from the neonatal units at both the Queen Charlotte's and Chelsea and St. Mary's hospital sites. Eligible participants will be identified by the clinical team and recruited by a member of the research team.
The vast majority of admitted infants will require nasogastric tube insertion as part of their clinical management such as preterm infants, sick term infants with hypoxic- ischaemic encephalopathy and meconium aspiration syndrome as well as admitted infants for hypoglycaemia and jaundice management.
Study method
The clinical trial will be a diagnostic accuracy study of two diagnostic tests and will be reported in accordance with the Standards for reporting diagnostic accuracy studies (STARD) guidelines. The index tests will be (i) the novel tributyrin impregnated pH test strip and (ii) standard pH test strip. The reference test used for comparison will be chest x-ray performed earlier or later but with the same nasogastric tube in situ; or where this is not required 'trial by use' (any chest x-rays undertaken would be decided and authorised by the participant's clinical team who are clearly separated from the research team. Undergoing a chest x-ray does not from part of screening for the study and is not a requirement of the study protocol).
Ingenza novel lipase/pH test strip
The test detects the organic acid released from tributyrin, a chemical ester impregnated onto pH paper by the action of human gastric lipase that is stable in gastric juice and resistant towards antacid medications, as well as unlikely to migrate. Ingenza have impregnated enteral pH indicator strips that are in current clinical use with emulsion formulations of tributyrin, protected by intellectual property as human gastric lipase substrates. Therefore, the novel test strips will provide a positive result in the presence of an acidic environment (pH less than or equal to 5.5) or gastric lipase.
Index testing
After the tube insertion, the carer will aspirate the tube to obtain a sample of gastric fluid. This will be done immediately following insertion or as part of daily position confirmation that is routinely performed prior to initiation of nasogastric feeding. The aspirate will be used by the healthcare professional, as part of routine care and the remaining sample passed to a member of the research team. The healthcare professional will test the aspirate routinely and make their decision based on the current standard pH strip test. The remaining sample will be used by the research nurse blinded to the standard test, to wet the gastric lipase enhanced pH test strip. The research nurse will then independently assess the results of the study test paper at two minutes. Digital photographs of both the routine and the study test papers will be assessed independently by member of the study team to verify the findings. The healthcare professional will be blinded to the results of the proposed test strip. The research nurse will record the results of the standard test strip only after documenting the result of the proposed test.
For standard pH strips a pH of ≤5.5 will indicate correct tube placement and >5.5 indicates incorrect nasogastric tube position. For the gastric lipase enhanced pH strip test a positive result will be determined according to the manufacturer's recommendations.
INCLUSION CRITERIA
All infants (preterm and term) who require the insertion of nasogastric tubes for supplementary enteral feeding as part of their routine clinical management
EXCLUSION CRITERIA
Clinically unstable, critically ill infants Infants undergoing palliative care Infants with bowel conditions such as necrotising enterocolitis, bowel obstruction
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Imperial College Healthcare NHS Trust
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All infants (preterm and term) who require the insertion of nasogastric tubes for supplementary enteral feeding as part of their routine clinical management
Exclusion Criteria:
- Clinically unstable, critically ill infants
- Infants undergoing palliative care
- Infants with bowel conditions such as necrotising enterocolitis, bowel obstruction
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity of standard and ingenza pH strips
Time Frame: 6 months
|
Where test sensitivity is defined as the proportion of pH readings that are equal to or below (<=) a certain cut-off when aspirates are obtained from tubes placed inside the stomach.
Stomach placements are confirmed either by chest x-rays, or in its absence, by clinical observations).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of chest x rays performed
Time Frame: 6 months
|
Number of chest X Rays performed to confirm nasogastric tube position after insertion and failure of detection of position using currently available pH measurement strips
|
6 months
|
|
Time to confirm tube placement
Time Frame: 6 months
|
Total time in minutes to confirm nasogastric tube position
|
6 months
|
|
Number of nasogastric tube attempts to get the correct pH
Time Frame: 6 months
|
Number of nasogastric tube attempts to get the correct pH
|
6 months
|
|
Specificity of standard and ingenza pH strips
Time Frame: 6 months
|
Where test specificity is defined as the proportion of pH readings that are greater than (>) a certain cut-off when aspirates are obtained from tubes placed outside the stomach.
Non-stomach placements are confirmed by chest x-rays or through reported adverse events.
|
6 months
|
|
pH readings obtained by standard and ingenza strips under all cut-offs
Time Frame: 6 months
|
pH readings obtained by standard and ingenza strips under all cut-offs
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 19QC5444
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neonatal Disorder
-
HonorHealth Research InstituteNeolightCompletedNeonatal Hyperbilirubinemia | Jaundice, Neonatal | Neonatal DisorderUnited States
-
Groupe Hospitalier Paris Saint JosephCompletedNeonatal Feeding DisorderFrance
-
Sudarshan JadcherlaRecruitingFeeding Disorder NeonatalUnited States
-
Rennes University HospitalCompletedNeonatal DisorderFrance
-
Maharishi Markendeswar University (Deemed to be...Not yet recruitingNeonatal Disorder
-
Red Salud Materno Infantil y del DesarrolloHospital Universitario 12 de OctubreCompletedNeonatal DisorderSpain
-
Indiana UniversityNational Institute on Drug Abuse (NIDA); Indiana Clinical and Translational...Not yet recruitingOpioid Use Disorder | Neonatal Opioid Withdrawal Syndrome | Neonatal Opioid Withdrawal | Intrauterine Exposure
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...UnknownFeeding Disorder Neonatal
-
Kahramanmaras Sutcu Imam UniversityRecruitingAnxiety Disorders | Breastfeeding | Neonatal OutcomesTurkey
-
Asir John SamuelMaharishi Markendeswar University (Deemed to be University); Department of...CompletedNeonatal Disease | Neonatal DisorderIndia